Diadema Partners »

C4 Therapeutics shares owned by Diadema Partners

Quarter-by-quarter ownership of C4 Therapeutics (CCCC) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in C4 Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including C4 Therapeutics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in C4 Therapeutics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $312k 141k 2.22

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding C4 Therapeutics

Lynx1 Capital Management
Soleus Capital Management
OrbiMed Advisors
Daniel D. Thurber
Morgan Stanley
Vanguard Group
Millennium Management
Silverarc Capital Management
BlackRock
Bain Capital Life Sciences Investors
Renaissance Technologies
Tang Capital Management
Two Sigma Investments
Two Sigma Advisers
Geode Capital Management

View all funds holding C4 Therapeutics